620161-75-3

Basic information

• Product Name: carbonic acid 2-tert-butoxycarbonyloxyMethyl-allyl ester tert-butyl ester
• Synonyms: carbonic acid 2-tert-butoxycarbonyloxyMethyl-allyl ester tert-butyl ester
• CAS NO: 620161-75-3
• Molecular Formula: C₁₄H₂₄O₆
• Molecular Weight: 288.33676
• Mol File: 620161-75-3.mol

Chemical Properties

• Boiling Point: 328.4±42.0 °C(Predicted)
• Appearance: Light yellow liquid
• Density: 1.051±0.06 g/cm3(Predicted)
• CAS DataBase Reference: carbonic acid 2-tert-butoxycarbonyloxyMethyl-allyl ester tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: carbonic acid 2-tert-butoxycarbonyloxyMethyl-allyl ester tert-butyl ester(620161-75-3)
• EPA Substance Registry System: carbonic acid 2-tert-butoxycarbonyloxyMethyl-allyl ester tert-butyl ester(620161-75-3)

Safety Data

• Hazardous Substances Data: 620161-75-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Carbonic acid 2-tert-butoxycarbonyloxyMethyl-allyl ester tert-butyl ester is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure, including the tert-butoxycarbonyloxyMethyl-allyl and tert-butyl ester groups, allows for versatile reactions and the formation of diverse drug molecules.
Used in Organic Synthesis:
In the field of organic synthesis, carbonic acid 2-tert-butoxycarbonyloxyMethyl-allyl ester tert-butyl ester serves as a valuable reagent. Its functional groups enable a range of reactions, such as esterification, transesterification, and other condensation reactions, contributing to the synthesis of complex organic molecules.
Used in Chemical Research:
Carbonic acid 2-tert-butoxycarbonyloxyMethyl-allyl ester tert-butyl ester is also employed in chemical research to explore its properties and potential applications. Further studies and analysis are required to determine its specific characteristics, reactivity, and suitability for various chemical processes.

Upstream product

• 3513-81-3 2-(Hydroxymethyl)allyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 32503-27-8 tetra(n-butyl)ammonium hydrogensulfate 

Downstream Products

• 1322645-26-0 9-cyclohexylmethyl-1-(4-t-butylbenzenesulfonyl)-3-methylene-5-(p-toluenesulfonyl)-1,5,9-triazacyclododecane 
• 1322646-04-7 9-cyclohexylmethyl-1-(4-chlorobenzenesulfonyl)-3-methylene-5-(p-toluenesulfonyl)-1,5,9-triazacyclododecane hydrochloride 
• 1322646-07-0 9-cyclohexylmethyl-1-(4-methoxybenzenesulfonyl)-3-methylene-5-(p-toluenesulfonyl)-1,5,9-triazacyclododecane hydrochloride 
• 1322646-10-5 9-cyclohexylmethyl-1-(naphthalene-1-sulfonyl)-3-methylene-5-(p-toluene-sulfonyl)-1,5,9-triazacyclododecane hydrochloride 
• 1322645-35-1 9-cyclohexylmethyl-1-(naphthalene-2-sulfonyl)-3-methylene-5-(p-toluenesulfonyl)-1,5,9-triazacyclododecane 
• 1322645-36-2 9-cyclohexylmethyl-1-(4-nitrobenzenesulfonyl)-3-methylene-5-(p-toluene-sulfonyl)-1,5,9-triazacyclododecane 
• 1322645-38-4 9-cyclohexylmethyl-1-(benzenesulfonyl)-3-methylene-5-(p-toluenesulfonyl)-1,5,9-triazacyclododecane 
• 1322646-18-3 9-cyclohexylmethyl-1-(5-dimethylaminonaphthalenesulfonyl)-3-methylene-5-(4-methoxybenzenesulfonyl)-1,5,9-triazacyclododecane hydrochloride 
• 1322645-42-0 9-cyclohexylmethyl-1-(2-nitrobenzenesulfonyl)-3-methylene-5-(p-toluenesulfonyl)-1,5,9-triazacyclododecane 
• 1322645-44-2 9-cyclohexylmethyl-1-(5-dimethylaminonaphthalene-1-sulfonyl)-3-methylene-5-(4-nitrobenzenesulfonyl)-1,5,9-triazacyclododecane 
• 1322645-59-9 9-benzyl-1-(4-methoxybenzenesulfonyl)-3-methylene-5-(ptoluenesulfonyl)-1,5,9-triazacyclododecane 

Relevant articles and documents

Successive Nucleophilic and Electrophilic Allylation for the Catalytic Enantioselective Synthesis of 2,4-Disubstituted Pyrrolidines

Successive nucleophilic and electrophilic allylation mediated by the bis-Boc-carbonate derived from 2-methylene-1,3-propane diol enables formation of enantiomerically enriched 2,4-disubstituted pyrrolidines. An initial enantioselective iridium-catalyzed t

An efficient large-scale synthesis of EDP-420, a first-in-class bridged bicyclic macrolide (BBM) antibiotic drug candidate

A multistep, practical, and cost-effective synthesis of novel bridged bicyclic macrolide drug candidate EDP-420 (1) is described. Starting from inexpensive and commercially available erythromycin A 9-oxime, the current chemical process involves a series of transformations: triacetylation, Pd-catalyzed O,O-bis-allylation (bridge formation), acid-catalyzed sugar cleavage, oxime reduction, acetylation, Os-catalyzed bridge olefin oxidative cleavage, Corey-Kim oxidation, bridge oxime formation, deprotection, and final purification. Multikilogram quantities have been synthesized.

Assembly of Terpenoid Cores by a Simple, Tunable Strategy

Oxygenated, polycyclic terpenoid natural products have important biological activities. Although total synthesis of such terpenes is widely studied, synthetic strategies that allow for controlled placement of oxygen atoms and other functionality remains a challenge. Herein, we present a simple, scalable, and tunable synthetic strategy to assemble terpenoid-like polycycloalkanes from cycloalkanones, malononitrile, and allylic electrophiles, abundantly available reagent classes.

Rapid synthesis of polyprenylated acylphloroglucinol analogs via dearomative conjunctive allylic annulation

Polyprenylated acylphloroglucinols (PPAPs) are structurally complex natural products with promising biological activities. Herein, we present a biosynthesis-inspired, diversity-oriented synthesis approach for rapid construction of PPAP analogs via double decarboxylative allylation (DcA) of acylphloroglucinol scaffolds to access allyl-desoxyhumulones followed by dearomative conjunctive allylic alkylation (DCAA).

6,11-3c-bicyclic 8a-azalide derivatives

Compounds of Formula (I), and pharmaceutically acceptable salts, esters, and prodrugs thereof: (I) are disclosed, wherein A, B, D, L, X, Y, Z and R2′, are described herein. The compounds exhibit antibacterial properties. The compounds of Formul

Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182

The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a). In particular, the present invention relates to processes and intermediates for the preparation of O-(2-amin

8A,11-BICYCLIC 8A-AZALIDE DERIVATIVES

The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforemen

TETRACYLIC BICYCLOLIDES

The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

Spirocyclic bicyclolides

The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforemen

PROCESS FOR THE PREPARATION OF T-11 BICYCLIC ERYTHROMYCIN DERIVATIVES

The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivatives. In particular, the presen tinvention relates to processes and intermediates for the preparation of a compound of formula (IX-c).